LINK LUDWIG AUGUST 2016 1 8 |Come Together IN THIS ISSUE San Diego Scientific retreat hosted by Ludwig by Ludwig hosted

LIFE-CHANGING SCIENCE 17 | Unboxed: Sangeeta Sangeeta Bhatia Sangeeta Bhatia, Ludwig MIT MIT Ludwig Bhatia, investigator Q &Awith

LUDWIG LINK | AUGUST 2016

Vice President for Communications President Vice Steinhardt Rachel Sincerely, reading! Happy laboratory. her in alive innovation of flame the keeps she Takehow out extraordinaire. to find mentor alook and scientist Bhatia—engineer, Sangeeta scientist, inventor MIT Ludwig with We interview an have here also in cells. stem is all about book illustrated colorfully Iwon’t here’s The but who, say ahint: book. a children’swith publications scientific of stellar portfolio off a topped just aswell. One lab the outside busy stay they seems it And awards. and accolades to win continue scientists Our noticing: We people aren’t only the research. to of Ludwig’s contributions recent a sampling) (of sampling cancer. asmall is just of all this ovarian And treatment for the immunotherapy experimental an and combination of checkpoint blockade, chemotherapy the to evaluate of atumor. atrial out launched They’ve cells are guided cancer breast metastasizing how parsed and therapy cancer to enhance repurposed be might that drugs identified biopsies, of liquid development the advancing studies published have lately scientists Ludwig LETTER proceeds apace. apace. proceeds progress that page, these in from the research featured Judging mission. of its pursuit in is making Research Cancer Ludwig progress the measuring Link the of issue ofI like each to think as a sort of milestone of milestone asasort Arshad Desai of Ludwig San Diego (left to right) (left of Diego Ludwig San Desai Arshad and Oegema Karen cover:Shiau, the On Andy LUDWIG LINK LUDWIG ludwigcancerresearch.org Aiming for moon Aiming the A transatlantic tap genies Gene achieversHigh sandbox Atop the Break-down resistance pioneer’sThe pioneer Awards and distinctions Steady hand Changing lanes movePeople the on Required reading Required ascientist Ask Bhatia Q &Awith Sangeeta youDid know ... Twinned targeting Silencing a suppressor Company news effects Lasting Three hits Clinical trials Stem cells, anybody? New ¬eworthy Sequences and consequences of sensitivity Virtues language Inflammatory to stability In service Pannet probe New purpose Early divergence Breadcrumbs to anexit To prepare anegg Countering transformation adeadly Three-fer to zap atumor News roundup Come together! notes Meeting TABLE CONTENTS OF

AUGUST 2016 AUGUST

1 1 1 1 1 1 1 1 1 1 2 1 1 1 2 1 1 1 1 1 5 2 1 7 6 5 5 5 5 4 4 4 3 2 2 1 1 0 0 9 9 8 8 8 8 7 7 6 6 5 5 5 4 4 4 4 3

LUDWIG LINK | AUGUST 2016 People on the move Ludwig Institute Lane David Sir future. administrative less and sciencey more his in best the David wishes community Ludwig The scientists. Ludwig’s of roster stellar to lead scientist world-class another to recruit firm search executive an with closely working currently is committee Ludwig’s search on tumor biology and cancer immunotherapy. exclusively almost focus will Branch The Switzerland. Lausanne, in Institute Ludwig of the Branch core new of a establishment the in role his was achievement David’s signature out, pointed CEO Ed McDermott and President Ludwig As model. operating new its solidsome steps in for building the future in line with took Research Cancer Ludwig leadership, his Under own research. his on more to focus of June end the at Director Scientific our as down stepped Lane David Sir CHANGING LANES

4 he said. said. he I’d if tried,” better it havejourney, planned Icouldn’t on my “In reflecting Ludwig. at discovery of scientific world the to Baer Julius and Merrill Lynch at to finance pharmaceuticals at Hoffman-LaRoche and Pharmavision route—from circuitous arather took Fred’s career board.” the on hand steady and presence reassuring CEO. his and miss will “We Ludwig’s president Ed Institute,”of the McDermott, said cancer and an unwavering commitment to the health of complexities the understand to better eagerness an researchers, of Ludwig work the in interest a keen demonstrated Fred meeting, board first very “From his ensued. that recession severe the of 2008 and crisis financial the weather us helped counsel wise and acumen financial His care. cancer transforming already are that commercially developed strategies and therapeutic being now are that treatments new have generated They fruit. bear and immunotherapy—mature in notably board—most its and by Ludwig championed ideas of watching pleasure the Fred had tenure, has his During Fund. Ludwig the and Institute Ludwig of the board the from down stepping is Fred Berger 13 years, After Ludwig Board Fred Berger STEADY HAND

LUDWIG LINK | AUGUST 2016 Awards and distinctions Ludwig Lausanne Ludwig Ho Ping-Chih Coukos. George Director Lausanne of Ludwig mentorship the under studies his conduct will editing.” Ping “immunometabolic by such to sleep therapies to awaken antitumor immune responses put new to is develop of research his goal ultimate The their to ability evade anticancer immune responses. to contribute cells of tumor processes metabolic unique the how to explore funding the use will He Immunotherapy of Research Cancer– Alliance. for Society Young the Award from Investigator a won has Ho Ping-Chih scientist Lausanne Ludwig cancer-causing gene, the human first the of discovery his with oncology of field the revolutionized Bob April. in Orleans New in Meeting Annual AACR the at Research Cancer in Achievement Award forLifetime (AACR) Research for Cancer biology with the Association 13th American annual cancer and research to cancer contributions seminal his for honored was Weinberg Robert Director MIT Ludwig and precisionand for medicine the treatment of . biology cancer of modern foundations the laid discoveries Rb gene, suppressor tumor known first of the BREAK-DOWN RESISTANCE THE PIONEER PIONEER’S

Ras oncogene, and the isolation . These . These

5 with anti-PD-1 checkpoint blockade therapy. tumors childhood mutated highly treating atrial proposed have hers and Crystal while immunotherapy, of efficacy the to predict models developing on focus will partner with his and junior Jedd researchers. in partnership submitted separately they proposals Award for research Collaboration in Innovation Sharp $200,000 A. Phillip a received each have scientists to Cancer–affiliated Up Stand Team, The aDream team any alone. you aren’t make would Crystal and Jedd that you thinking has If this companies. pharmaceutical nonprofit health organizations and biotechnology and with partnerships as well as centers, university-based six includes institute The property. to intellectual claims together without compromising or complicating their work can researchers affiliated which in innovation, forscientific “sandbox” avirtual calls he to what create wants Parker immunotherapy. cancer of field sizzling already the in progress to accelerate seeks institute new the Facebook, and of Napster Parker Sean entrepreneur by a$250 tech with grant million Established institutions. for Cancer Immunotherapy at their respective home Institute Parker Francisco–based San of the directors center as tapped have been Mackall Crystal investigator Stanford’s Ludwig and Wolchok Jedd MSK’s Ludwig Ludwig MSK Jedd Wolchok ATOP THE SANDBOX Ludwig Stanford Mackall Crystal

LUDWIG LINK | AUGUST 2016 Awards and distinctions Ludwig Johns Hopkins Kenneth Kinzler prestigious given honors to researchers. academic most of the one is Membership NAS. to the elected 14 from countries associates foreign new 21 and members new 84 were among two The . prostate and breast as such malignancies, human in role their and receptors steroid on work for his recognized widely is Myles genomes. cancer analyzing and forsequencing novel methods developed and responsible for the formation of human tumors, a pivotal role genetic alterations the in defining research.” played Ken has original in achievements in recognition of their “distinguished continuing and (NAS) of Sciences Academy National to the elected Brown have been Myles investigator Harvard Ludwig and Kinzler Kenneth Co-director Hopkins Johns Ludwig HIGH ACHIEVERSHIGH

Ludwig Harvard Brown Myles

6 their businesses and communities.” such areas as innovation and personal commitment to in success extraordinary and excellence “demonstrate which recognizes entrepreneurs who outstanding program, awards EY of the anniversary 30th the marks dispensation of personalized cancer therapy. This year the development and supports DNA testing services cancer high-quality art, of state-of-the menu growing company’s The patients. cancer from biopsies liquid and characterize genomic alterations in tumors using tissue to services testing and analysis genome cancer advanced provides cancer. as such company The diseases related age- to address it mine and data of genomics wealth The researchers launched to PGDx harness the current category. technology innovative the in region Maryland Year of the &Young Entrepreneur the Ernst award in EY 2016 the have received (PGDx), Diagnostics Genome of Personal Velculescu, cofounders Victor colleague his and Diaz Luis scientist Hopkins Johns Ludwig Ludwig Johns Hopkins Diaz Luis GENE GENIES GENIES GENE

LUDWIG LINK | AUGUST 2016 Awards and distinctions Calle Heldin Ludwig Uppsala on October 8 in Cambridge, Massachusetts. Cambridge, 8in October on a ceremony at inducted formally be will Karen and Calle leaders. philanthropic and business civic, as well as artists, and writers scientists, scholars, accomplished most world’s of the some include academy of the members 213 new The of cancers. all half about in mutated is which genome, of the guardian so-called , the on expert an is She UK. Research forCancer scientist of chief post the up taken recently has and Scotland, Glasgow, in Institute Beatson UK Research Cancer the of director the been has Branch, Mary’s St. the at group papillomavirus human of the head and member assistant Ludwig aformer Karen, by night. Laboratory for Life Science the and Foundation Nobel of the board the of by day, chairman and biologist amolecular is Calle Sciences. and of Arts Academy American of the members elected were Ludwig, to advisor Vousden, ascientific Karen and Heldin Calle Director Uppsala Ludwig A TRANSATLANTIC TAP TRANSATLANTIC A

Committee Ludwig Scientific Advisory 7 [email protected] Moonshot’s the on to updates by subscribing initiative the in engage can public the and community research of the Members sharing. to data detection to early vaccines cancer from develop recommendations for the NIH on everything and initiative Moonshot the guide help will It advocates. patient and leaders industry researchers, of cancer a pool from panel the (NIH), convened of Health Institutes National of the part Institute, Cancer National US The initiative. Moonshot Cancer Biden’s National Joe President Vice US advising for apanel cochairs of three one Tyler named was investigator MIT Jacks Ludwig Ludwig MIT Tyler Jacks AIMING FOR THE MOON

main website . or by emailing the panel at at panel the by emailing or

LUDWIG LINK | AUGUST 2016 Meeting notesMeeting photographer extraordinaire for the day! forthe extraordinaire photographer as forserving Li Binzhong postdoc Diego San to Ludwig thanks Many event. the from snapshots atwo are Here community.” Ludwig the in everyone with forinteractions venue awonderful provided retreat “The forresearch. president vice executive Strausberg, Bob in research cancer to future career opportunities,” said advances current from ranging areas, many spanning discussions informal in to engage opportunity an team York New the provided leadership and development, career early-stage at those especially scientists, of forall our experience great was “It posters. and presentations in research their to share postdocs and forstudents forum ideal an proved to be Branch Diego Ludwig’sSan by hosted recently retreat A scientific to face. face colleagues meeting beats nothing be, can technology communications century 21st as amazing As COME TOGETHER! TOGETHER! COME 8 News roundup employed by cancer cells. by cancer employed suppression of immune akey mechanism disabled by the immunotherapy—a PD-L1 antibody—which boosted then was response That tumors. into the T cells response, the immune activated drawing vaccine-primed survival. The researchers propose that radiotherapy their extended and mice tumor-bearing in growth cancer’s the slowed tumor. also the treatment The into flooded T cells killer activated immunotherapy, blockade by followed checkpoint radiation and vaccine acancer with mice tumor-bearing treated they when 13 Oncotarget of issue June the in report They interventions. of sequential astrategy with recalcitrance investigated whether they could this undo malignant Weichselbaum by Ralph led researchers of Ludwig A team tumors. these infiltrate Tcells few activated because probably is This short. up come has block, the on therapy harder to treat. Even immunotherapy, the hottest even and to diagnose hard is cancer Pancreatic Ralph Weichselbaum Ludwig THREE-FER ATUMOR TO ZAP

that that

LUDWIG LINK | AUGUST 2016 News roundup the activation of these intracellular receptors appears to appears receptors intracellular of these activation the that shows also paper Their LXRs. as known receptors occurring cholesterol nuclear metabolite, activates anaturally compound, such one reveal that studies their Reports of Scientific 19 issue July the in The researchers intact. factor the of effects other,the tumor-suppressing thatbut leave might reverse effects pathological these forchemicals to screen Diego San in Program Discovery Molecule Small Ludwig of the Gahman Timothy and Shiau Andy including of researchers ateam led Uppsala of Ludwig Heldin Calle and Moustakas Aristidis tumors. and organs in tissue of fibrous buildup the drive that epithelial cells—which cavities—into line body agents turn also can It metastasis. cell cancer promotes and mobile cells makes that transformation internal dramatic epithelial-to-mesenchymalinducing transition (EMT), a by is so way does it important An of tumors. progression to the contribute surely as just can it dysfunctional, are signals it by which pathways biochemical the when or active, chronically is it when But tumors. suppress can messenger RNAs, which are transcripts of genes ready ready of genes transcripts are which RNAs, messenger CSR-1 selected to slice called enzyme an show, direct roundworm Caenorhabditis elegans. The they small RNAs, of the egg fertilized the of in proteins balance perfect the create help molecules RNA small certain how shows development. Their study of embryonic steps earliest forthe stage biochemical the sets egg roundworm akey the discovered way which in have Desai by Arshad led researchers Diego San Ludwig Transforming growth factor-β (TGF- TO PREPARE EGG AN COUNTERING ADEADLY TRANSFORMATION report the discovery of such molecules molecules of such discovery the , published April 7 in Cell 7in April , published β ) is a protein that that aprotein ) is . Significantly, , 9 fibrosis and cancer. and fibrosis tissue to treat for drugs targets useful be could LXRs of EMT-inducing the TGF- counter effects Aristidis Moustakas of development. steps first forthe of required proteins balance precise the to achieve RNAs small and protein Argonaute an use too mice since organisms, to higher of relevance their internal composition. Their findings are likely tobe proteins known as Argonautes—eggs precisely can tune of RNA-silencing to afamily belongs enzyme—which CSR-1 to the bound RNAs of small number the by varying for translation into proteins. The researchers that report Discovery Program Ludwig Small Molecule Shiau Andy Ludwig Uppsala

Discovery Program Ludwig Small Molecule Timothy Gahman Ludwig Uppsala Calle Heldin

β , suggesting

LUDWIG LINK | AUGUST 2016 News roundup patients, and confirm that high levels MENA of high that confirm and patients, show that MENA that show behavior. colleagues invasive his to drive known and Frank Ludwig MIT Frank Gertler by MENA promoted is process This escape. can they where from vessels, blood of vicinity the and tumors of periphery the to fibronectin of follows agradient that apath to take appear mice in cells cancer breast invasive that show researchers Cancer in May Discovery in published apaper In answer. an found just has Gertler Frank MIT’s by Ludwig however, clear. led less of been researchers Ateam has is, role that What metastasis. cancer in arole to play known been long has fibronectin tissues, of cells solid the supports that matrix extracellular of the A component poorer survival. and recurrence cancer breast higher with correlate and MENA fibronectin that report researchers The migrate. can cells cancer the which along rails stiff forms which collagen, protein, matrix extracellular of another structure the alter to fibronectin drives turn, in event, That fibronectin. with BREADCRUMBS TOBREADCRUMBS EXIT AN INV

levels are correlated in cancer breast in correlated are levels INV boosts the cancer cell’s interaction cell’s interaction cancer the boosts INV , a protein in cancer cells also also cells cancer in , aprotein , the , the INV

10 Ludwig Stockholm Ludwig Rickard Sandberg and regenerativeand medicine. research , stem to developmental value of be will study this from generated data expression gene The stage. early this at chromosomes other on those from differently very regulated are Xchromosome human the on genes that report further They mice. in do they than embryos human in simultaneously more mature and later form stage this at emerge that types cell precursor days of development. They that report three distinct seven first over the patterns expression gene and course developmental their in significantly differ embryos human and mouse that show researchers the embryos, human early 88 from cells individual 1,529 in expression gene answer.global an of analyzing installment By first the up colleague Fredrik of the Karolinska Lanner Institutet serve his and Sandberg Rickard scientist Stockholm Ludwig of life? stages astudy In earliest these in differ matter. they forthat do how So women, or men, not are mice But development. embryonic forhuman models as used routinely are embryos Mouse EARLYDIVERGENCE published May 5 in Cell 5in May published ,

LUDWIG LINK | AUGUST 2016 News roundup Ralph Weichselbaum DNA. cell to tumor damage oxidative boost to seem like it) (and others antibiotic The tissue. healthy to toxicity increasing without mice in growth tumor slows significantly radiation and cephalexin with treatment 25 Oncotarget in April online radiosensitizer. findings The apromising as States, United the in drugs generic prescribed commonly most the of one cephalexin, antibiotic the identified process This melanoma. of radioresistant model mouse in a them evaluated and effective, possibly and safe be to appeared that agents 19 identified team the products, natural and drugs molecules, investigational existing of screen alarge-scale conducting After radiation. of effects the enhance might that agents available find to out set Weichselbaum Ralph Co-director Chicago by Ludwig led researchers of Chicago of University Ateam scratch. from ones new of developing process costly and time-consuming the to bypass means apractical as traction gained has drugs, existing for found are uses new which in repurposing, Drug Ludwig Chicago NEW PURPOSE PURPOSE NEW

, show that combined combined that , show , published , published 11 extended survival. survival. extended engulfment by macrophages, blocked metastasis and promoted growth, tumor inhibited model amouse in antibody anti-CD47 an with tumors the Hitting system. frontlinewhich of soldiers are the immune important to macrophages, me’ a‘don’tsignal eat transmits that CD47. as well as CD90 protein areceptor is latter The surface cell of levels the high express which and active, A1 highly is dehydrogenase aldehyde named enzyme an which in cells of PanNET population aggressive a very of the of activation and receptor factor growth hepatocyte the via by signaling driven are they that showing tumors, these of biology the characterized Krampitz Geoffrey and Weissman Irv scientists by Ludwig led researchers study of Sciences Academy National 19 April an In challenging. clinically Pancreatic (PanNETs) tumors neuroendocrine are Ludwig Stanford Stanford Ludwig Weissman Irv PANNET PROBE MET proto-oncogene. The researchers identified Ludwig Stanford GeoffreyKrampitz , a team of Stanford of Stanford , ateam Proceedings of the of the Proceedings

LUDWIG LINK | AUGUST 2016 News roundup Richard Kolodner none. has instability, genome little with a cancer leukemia, myeloid acute whereas genes, GIS their in defects more or have one cancers 66%and of colorectal 93% cancer. that with found of ovarian They associated are that genes to GIS formutations Atlas Genome Cancer the to search information this used then They themselves, play role some in suppressing instability. genes GIS not though that, genes” GIS “cooperating 438 before—and described been hadn’t of which (GCRs) yeast—98 in rearrangements chromosomal of gross modifiers 182genetic identify to first method 13 Nature in CommunicationsApril reported researchers The genes. such to find genetics fromcombines methods bioinformatics yeast and Christopher Putnam has developed an approach that and Kolodner Diego’s Richard San by Ludwig led however. identified, Nowof a team researchers have been (GIS) genes instability–suppressing genome such all Not errors. genetic large-scale other and of chromosomes genes that in one way or another prevent rearrangement of cancer. have evolvedapassel cells least not So any cause can genome unstable of number An problems, Ludwig San Diego IN SERVICE TO STABILITY

Ludwig San Diego Christopher Putnam how they used their their used they how

12 chronic inflammation and cancer. and inflammation chronic between link notably, akey is, molecular factor This to the nucleus through a factor named NF- named afactor through nucleus to the transmitted are signals its and bacteria, NOD2, detects receptor. immune receptor, by innate This an signals of inflammatory transmission the regulate molecules protein complexes that or add remove either ubiquitin Reports paper 29 aMarch In them. among are team his and Gyrd-Hansen Mads scientist Oxford Ludwig each. of effects the and cell, the within used are ofhow chains various permutations ubiquitin its and processes— other those in of ubiquitination language the out to figure race aheated in currently are Scientists division. to from process, cellular major every much pretty in role acritical to play appears protein the implies, name its As of death. kiss molecular a just isn’t ubiquitin But degradation. and for disposal another protein them which ubiquitin, named marks way with aparticular in tagged often are usefulness their have outlived that to proteins go, time it’s When forever, lasts exception. no are proteins Nothing and Ludwig Oxford Mads Gyrd-Hansen INFLAMMATORY LANGUAGE INFLAMMATORY , they describe how a series of proteins and of and proteins aseries how describe , they κ Cell Cell in B. B.

LUDWIG LINK | AUGUST 2016 News roundup Ludwig Stanford Maximilian DiehnMaximilian cancer patients. lung of non-small-cell blood the in fragments DNA 400,000 as nontumor many as among sequence DNA tumor few one as as detect could iDES that found captured and prepared for The researchers sequencing. is DNA tumor circulating when occur that errors Biotechnology issue May the in described and (iDES) integratedtechnique—dubbed digital error suppression new The of cancers. treatment the personalize and ofability physicians to diagnose, routinely monitor liquid biopsiesused, would also greatly improve the frequently more be can they Because biopsies. surgical discomforts and complications that can accompany of the free therefore and invasive less far are which companies are rushing to devise such diagnostic tests, biotechnology and Researchers blood. into the tumors by shed DNA profiling and fordetecting technique new accurate and sensitive aremarkably with biopsy” “liquid toward areliable step agiant have taken Alizadeh Ash and Diehn Maximilian scientists Stanford Ludwig VIRTUES OF SENSITIVITY —detects and computationally—detects removes

Ludwig Stanford Ash Alizadeh of Nature of

13 Ludwig Oxford Bond Gareth Nature Reviews Cancer Reviews Nature in April were published findings The strategies. treatment and surveillance cancer in implications have important could which cancers, to promote known mutations of acquired to those similar characteristics to have genetic appear cancers with associated are p53 that pathway the in SNPs inherited pathway. the this more, What’s along occur (SNPs) that sequence known as single nucleotide polymorphisms DNA in variations forinherited true holds same the that demonstrated and data trove avast of genomic mined has Bond Gareth Oxford’s by Ludwig led of researchers team international an Now of cancers. variety awide in pathway of other any those than role abigger genome—play of the guardian the dubbed p53—a protein involving pathways biochemical the influence that mutations gene Cancer researchers have long known that spontaneous CONSEQUENCES SEQUENCES AND .

LUDWIG LINK | AUGUST 2016 New ¬eworthy what you’re looking for in Irv’s book. book. Irv’s you’re forin what looking Link sorts, all takes (it banter party forcocktail- grist collect or third-grader foryour gift a get flow of whys, six-year-old’s your ceaseless stanch you’re to whether So hoping regrow limbs. can animals to some how grow taller plants and itself heals body the how from everything explains book 46-page The IQs. biological to their afew notches add then, until someday—and, of to them many relevance of medical likely to be asubject on aprimer grownups science-shy give himself. also It’ll of Irv three illustrations—including in plainwritten English cartoony flush and withbright, is book the to nine-year-olds, forseven- written and Everywhere Stem are Cells Titled cells. stem subject: favorite we suspect, and, bailiwick his on for kids a book published just has Weissman Irv Director Stanford Ludwig researchers.) our We support aplug. it to call free (Feel kids? forthe Ludwig apresent Link Need STEM ANYBODY? CELLS, says), you’ll find has a suggestion. 14 Clinical trials are the leading trial. Arizona, in Center Medical and Joseph’s Hospital St. at oncology of gynecologic director Monk, Brad and Coukos George Director Lausanne study.the Ludwig VentiRx Pharmaceuticals—are also collaborating on firm biotech the and of AstraZeneca, subsidiary of the investigational a therapies—MedImmune, manufacturers The CRI. and by Ludwig managed jointly is which Trials CVC the Network, through conducted being is trial The antigens. cancer ‘see’ system immune the by helping by durvalumab engaged not are that cells cancer against responses immune boost when given with chemotherapy, motolimod could Further, durvalumab. of effects the enhance will TLR8 of activation motolimod’s that expect Researchers response. immune innate of the initiator an is and cells of immune avariety in found is TLR8 doxorubicin. chemotherapeutic agent PEGylated liposomal the with agonist, aTLR8 motolimod, and PD-L1, a checkpointdurvalumab, blockade antibody against of combination the assessing is cancer. study The of combination immunotherapy for advanced ovarian an international, multicenter phase 1/2 clinical trial in of patients cohort initial the dosed successfully (CRI) Institute have Research Cancer the and Ludwig George Coukos Coukos George Ludwig Lausanne Ludwig THREE HITS HITS THREE

LUDWIG LINK | AUGUST 2016 Clinical trials Ludwig Harvard Stephen Hodi cancer, and accelerated approval for . forlung approval cancer, accelerated and of colon subtypes certain and lymphoma for Hodgkin’s has also received breakthrough therapy designation antibody Carter. The Jimmy President US former to treat famously, recently, most used was and drug the and formelanoma approval accelerated gave pembrolizumab Administration Drug and 2014, In Food the response. immune antitumor the on imposed brakes the lift can so and receptor that blocks Pembrolizumab attack. to suppress receptor PD-1 the year. engage cells Cancer a exceeded rarely melanoma advanced with diagnosed people of survival median the ago, five years Just complete remission, 89% have remained in remission. experienced who trial that in 15%of the of patients later. years impressively, three as alive were still Just inhibitor pembrolizumab (Keytruda) in a 1b phase trial PD-1 the with were treated who melanoma advanced with 40% of that May 655 in patients Chicago in of Clinical Society meeting Oncology the American at reported Harvard, Ludwig at aresearcher Hodi, internationalAn team of scientists including Stephen LASTING EFFECTS EFFECTS LASTING

15 Company news Company bladder, ovarian, lung and other solid cancers. for atherapy as evaluation clinical and preclinical its and separately. The grant will the fund manufacture of IMM65 fight tumorsbetter than either of its cancomponents will IMM65 nanoparticle resulting the that anticipates iOx Ludwig’s with NY-ESO-1 vaccine. tumor agonist iNKT iOx’s combines that product of anew development the support will grant The iTeos Therapeutics. spinout, international consortium that includes another Ludwig of an part is company The immunotherapies. cancer new to develop Union 2020 European the from grant immunotherapy spinout, received a million €8.3 Horizon University Oxford and aLudwig Therapeutics, iOx Université de Louvain catholique in Belgium. of the Institute Duve de the with collaboration Ludwig antitumor immunity. The initial research stems from a of modulation their counteracting cells, by Tregulatory TGF- of active production the blocks to GARP antibody of the Binding responses. immune to suppress by tumors co-opted often are which cells, of Tregulatory membrane the on GARP. protein found is the GARP targets that antibody ARGX-115, commercialize apreclinical-stage and to develop collaborate will companies two The cancers. biotech that firm develops antibodies to treat therapeutic with argenx, a clinical-stage development partnership into a entered has AbbVie company pharmaceutical The SILENCINGSUPPRESSORA TWINNED TARGETING TARGETINGTWINNED β 1

LUDWIG LINK | AUGUST 2016 Did you know… brain are better at these things than the world’s finest world’s finest the than things these at better are brain recognitionpattern or creativity. The human eye and involve tasks complex Many not. is it often, too but stuffmay seem like job theperfect for a supercomputer, of the terabytes through Sorting of data. atsunami in lost themselves find of fields avariety in scientists processes, automation of many research and data-collection sequencing, imaging and sensors and the general genome in to advances Thanks aneed. There’s certainly disease. and genetics between links to the day—from change of our climate problems scientific biggest of the some tackle help by playing, merely and, up to team players get games Their analysis. data in challenges nettlesome to address games of video lineup proliferating to now arapidly create years several for programmers with up teaming have been Scientists age. digital of the wonders the are Such fact. in Lifesaving, useful. be can Gaming into avirtue. obsession your even turn yourself. You Maybe news: excellent redeem now can thumbs?and tapping Well, screens luminous of blur in a lost life of finite your Terminally Tetrised? minutes many too Bejeweled? Are Crusher? Brazenly Candy you acompulsive Are DID YOU KNOW... Ludwig Link has some some has 16 Check it out. Lab coat optional. coat Lab out. it Check any interest at Zooniverse. foralmost opportunity volunteer or game crowdsourced You’ll free, Serengeti. a find Vision: Computer at savanna African vast the from images you on like, work animals it’s if Poppin’ at Galaxy; images space deep classify help you excite can you, cosmos awesome of our reaches far the If research. cancer of fields—including variety fora analysis to DNA to Phylo contribute play could brain? of the Well, Eyewire’swiring you Or game. your the today. Want science real-life chart to help some to do geek inner your channel you can anewbie, or nerd you’re whether agaming that is here point main Our the game’s honor. PH1 in named was planet The orbit. their in exoplanet aNeptune-like holding of stars four system solar strange playing gamers Planet HuntersAmerican discovered a later, Ayear for 15 years. of apair computers their and scientists stumped had that weeks three in structure protein aretroviral solved Fold.It playing 2011,In gamers computer.

LUDWIG LINK | AUGUST 2016 Q &Awith Bhatia Sangeeta artificial organs. organs. artificial disease, monitor the and body make human my we’re lab to model them using regeneration and cancer therapeutics. In toxicity, like drug tissue problems complex to tackle tools these borrowed we’ve So diseases. infectious and cancer like challenges health human address allow usto now that of technologies have aset created faster chips computer to make our instruments creating into have gone that by engineers work of decades The pockets. our in around for usto carry enough small became they when lives our transformed computers how about Think miniaturization. in invested have been of dollars Billions important? technologies Why are tiny let go. never has and of me hold grabbed health human to impact instruments use could engineers that idea therapy, the and for cancer tumors to heat ultrasound focused to use was trying who at MIT engineering mechanical in friend family a to visit me took He was. engineering of what conception no had but tinkering, liked and science and math in I was strong I’d thought agreat engineer.my dad be entrepreneur. school high Iwas in When or were doctor, to me open engineer paths career I like three to the joke that immigrants, of Indian daughter the As innovation?medical for industry computer the in developed technologies you to adapt inspired What Unboxed: Sangeeta Bhatia, Ludwig MIT investigator around the world use them. We’ve them. use also world the around Today, trials. clinical over 40 companies cells before liver doing in metabolism and safety drug to test companies and distributes them to pharmaceutical at scale micro-livers the manufactures which Ascendance, called company aspin-off through commercialized is being liver. the infect platform uniquely Our that pathogens the study also and liver to the harmful are potentially that drugs new test to them We use cells. can neighboring supportive cells amidst liver human of colonies to ‘print’ microfabrication by using techniques for semiconductor micro-livers human artificial We developed How are micro-livers in used research? 17

LUDWIG LINK | AUGUST 2016 Q&A residential program here at MIT. here program One residential summer undergraduate is an which Women’sto the Technology Program, and engineering. Several have gone on science in careers to pursue inspired have been and program the through have come who girls from anecdotes of lots and of experience 23just years We don’t have comprehensive data— career? a as engineering and science to pursue Youth in been encouraging young girls Keys to Empowering has successful How regulatory and commercial landscapes. oncology, science, of our nexus sit at the that questions many raises This to patients. this technology bring how to out figure mice). (in to type Wetumor need now for this methods imaging or biomarkers blood existing than sensitive more asmetastasis). far,known So is test the (a liver to the process cancer of colon spread the involved with proteases of of apanel detection ultrasensitive on We urine. are working patient’s a in are detectable that biomarkers of hundreds release of can which each proteases, called enzymes associated tumor- with interact that nanoparticles on relies that atechnology We developed project. detection cancer is our moment at the involved with I’m that very One child. afavorite to pick likeThat’s trying now? you right energizes really project What hepatitis hepatitis C, B and malaria. as such liver the affect that diseases infectious to study micro-livers these used

how they can play a part in it. Whether it’s Whether it. in apart play can they how And lives. all of our impacts engineering much how appreciate and understand to begin they wetechnology, hope coolest the with filled alab in experience scientists and and engineers get hands-on to be training women see and workshops Saturday of our to one have been girls these Once you. can’t see people if model arole you can’t be Ibelieve press, to the talk not and lab the in to stay comfortable more be can it While visible. myself for making motivators main of the are one like this Stories engineering. biomedical in studies graduate she’sand pursuing now Mellon was at Carnegie she uswhile with research doing asummer to spend her at MIT. exposure early by her We invited influenced her granddaughter hadbeen how to say out reached grandmother her to usbecause came student 18

can’t you. see model if people can’t arole be I believe you to the press, lab and not talk to stay in the comfortable morebe can it While

LUDWIG LINK | AUGUST 2016 Q&A sharing ideas and working hard together. hard working and ideas sharing of everyone innovation, and of creativity product is the we accomplish Everything ateam. Ilead anything, than for More me. these disparate roles into a cohesive one all inventor crystallized inspirational an as recognized being So, box. into any one neatly Idon’t fit of immigrants, daughter a and advocate entrepreneur, adiversity engineer, adoctor, educator, an an an ascientist, As generation. next the inspiring and for invention prolific for both award is given The incredible. It was truly Prize? Lemelson-MIT to the win itfeel did How 50-fold. by about situ in grow organ an help can approach combination we’ve this shown recently Chen’s Chris University, with at lab (like triggering regeneration). Together methods scale-up biology with printing) (like 3D methods scale-up engineering we’re is to pair approach One taking apatient. of cellsbillions to support with aliver we need of scale: problem is the challenges biggest of the One decade. next the in done be I’ll doubtful away, years remain it’s trials so clinical and difficult’ lifetime of ‘truly category Itis the in challenge. is agrand need in for patients demand on available to be like liver, the tissues, complex Engineering from scratch? aliver are you to engineering close How it. behind gadget they’re playing with, engineering is new whatever or smartphones their inside

way, too. biggest breakthroughs have happened this of our some again, then but anywhere, go never of them Some ideas. productive into wonderfully turn projects these all Not of inspired. to be curious, to stay To playing. creativity, spark tinkering—just we what call doing projects important and difficult of their outside time their 20% of spend students group, Ihave the my in fun process invention keep the to order in So profession. this you chose why you’reway to remember why and here a to be needs there Ithink themselves. for apath to carve trying people brilliant of are full institutions elite the and Cambridge is a veritable pressure cooker slow. of top that, On unreasonably seem can of research pace the and rate failure We’re ahigh has that aprofession in lab? your in of tinkering aspirit to encourage itimportant Why is present. and past team, award whole is really for the the So, 19 inspired. inspired. curious, to be creativity, to stay Toplaying. spark tinkering—just what we call doing projects important difficult and of their outside 20% of their time students spend I have the

LUDWIG LINK | AUGUST 2016 Q&A to come in the next 20 years. Iwouldn’t 20 years. next the in to come going is definitely impact immunotherapy’s Broadening of patients. asubset in durable remissions that have emerged is the immunotherapy about promising really been has that thing One approach. same to the vulnerable to be allnot going they’re and diseases, over 200 different is cancer is that we know what now And we didn’t away in makeup that before. molecular its understand we deeply where years, 10 last over the milestone a new reached has of cancer understanding Our changing? of cusp the on therapy cancer Is armamentarium. our in be will still tools like of many these now,looks eventhough it fromwhat different abit quite will be like will 20 it in look what years collectively Ithink methods. monitoring noninvasive and now development of next-generation tests, blood then imaging, molecular then and imaging anatomic do you could then (feel) to for palpate amass, you had that that to be Itused side. detection the on immunotherapy. There’s a parallel story of development the and therapies targeted weNow have molecularly chemotherapy, followed by radiation. then surgery, we did beginning the In of modalities. accumulation an as treatment of cancer trajectory the Maladies of All Emperor The wrote who Mukherjee, Siddhartha care. of cancer future the It’s to predict hard waynow? the treatfrom it we different drastically to be going is we cancer treat way the you think do 20 years, next the In , framed

forward with my own trainees. with forward that to pay hard myself. in Isaw than Itry me in more saw and me in believed He engineer. an be Ishould said asmy dad just aprofessor be Ishould to me tell person first zone, was the and my comfort beyond way me to push me in belief the and the foresight had He influential. most mentor. afantastic the was also and He advisor was my graduate Hospital, General Mass in embedded alab with School, Medical at Harvard faculty the Toner,to. Mehmet on engineer is an who up Ilooked that mentors male incredible of have aseries Idid role model. living Ireally didn’t have asingle perspective, ascientific Prize. from But Nobel the won also daughter older whose laureate aNobel and amother scientist, amazing an was She Curie. I have loved Marie always model? role influential most your was Who area. agrowth absolutely it’s but apanacea to be it’s going that say 20

LUDWIG LINK | AUGUST 2016 Ask ascientistAsk Is crowdsourcing hype or here to stay? Ludwig Lausanne great ideas! just not data, those to collect for grants compete before you can data need system—you is a‘catch-22’There traditional the in proof-of-principle creative, high-risk, projects. to launch researchers less-established for resource important an is potentially and crowdsourcing to stay is here that I think Uppsala Ludwig trust. to keep their donors to their feedback continuous provide and standards ethical following high projects their conduct must scientists to last, for crowdfunding However, interests. and order in finances to their according to donate public a wider for and funding extra to get for scientists both Itallows Crowdsourcing to stay! is here York New Ludwig studies and for employing research personnel. biomedical long-term for resource-intensive, support of ensuring means reliable are more which sources, funding traditional is replace unlikely to fully mechanism However, public. to the research funding of this their relevance the communicate to how learn and ideas new to explore is agreat way for scientists Crowdfunding MELITA IRVING PUIGSUBIRA CAJA LAIA LINDA FOIT 21

LUDWIG LINK | AUGUST 2016 Required reading Speiser DE. Speiser M, Delorenzi S, Waldvogel N, Rufer N, Montandon S, Maillard Abed M, Allard PO, Gannon L, Cagnon C, Soneson SA, Marraco Fuertes fever vaccination profilenaïve-like upon yellow a with Tcells CD8+ memory stem cell-like Long-lasting 2015 8 April Science Translational Medicine DE. P, Romero B, Speiser Weide O, P, Michielin C, Ballabeni Meyer P, Baumgaertner PG, Foukas M, Kusio-Kobialka E, Romano melanoma patients in monocytes nonclassical by vivo ex Tcells regulatory of cytotoxicity mediated cell- Ipilimumab-dependent 12 May 2015 USA Sciences of Academy Proceedings of the National Lausanne Ludwig Weichselbaum RR. SJ, Kron HG, Sutton AC, Flor EV, Efimova HJ, Mauceri E, Labay radiosensitizers antibiotics as pro-senescent Repurposing cephalosporin ahead of print] 25 2016 [Epub April Oncotarget RR. Weichselbaum Fu Y-X, MC, MT, Posner Spiotto H, Liang A, Arina C, Fernandez B, JP,Namm Burnette KB, Skowron B. W, Kinga Zheng checkpoint blockade resistance and vaccination overcome Combination of radiotherapy 2016 13 June Oncotarget Ludwig Chicago Bell DA, Bond GL. Bond DA, Bell B, Schuster-Böckler S, F, Landi P, LF, Sætrom Gemignani Thomas WG, Fairbrother KJ, Cygan CR, F, IP,Giner Goding Tomlinson J,Castro- J,Zeron-Medina Hewitt P, Zhang AM, Grawenda MD, Wallace X, Wang G, Stracquadanio somatic cancer genomes genetics in inherited and The of importance p53 pathway April 2016 Cancer Reviews Nature B Boeckler S,Kriaucionis Schuster- M, McClellan M, Tomkova frequency in human DNA regions with reduced mutation marks5-hydroxymethylcytosine of print] 2016 ahead 16Elife May [Epub X. Lu MR, Muers M, Lu binding are non-DNA transcriptional regulators that Introducing STRaNDs: shuttling ahead of print] 2016 25 [Epub May Biology Nature Reviews Molecular Cell Oxford Ludwig FB. Gertler AS, AV, Meyer Kwiatkowski M, J, Vidaki Veen van Edward RE, McConnell axon repulsion Robo-mediated extension toward Slit during A requirement for filopodia 25 April 2016 Biology Cell of Journal FB. Gertler JE, Bear PJ, Keely DA, Lauffenburger RO, Hynes KB, Wisinski MJ, Cima R, D, Langer C, Ma Whittaker SB, Asokan JM, D, Lamar Riquelme J, Wyckoff BC, Guido LC, Broye T, O, Kosciuk Jonas MJ, Oudin progression haptotaxis during metastatic matrix remodeling enables Tumor extracellular cell-driven 2016 May Discovery Cancer MIT Ludwig .

22 Desai A. K, Yeo R, GW, Oegema Green S, Sathe S, Wang A, Gerson-Gurwitz embryonic divisions transcript levels to ensure pathway tunes germline argonaute RNA-catalytic A small 7 2016Cell April Kolodner RD. SJ, AF, Souza de Fonseca ES, Souza de SB, Somach SN, Bell SP, Clotfelter SL, RV, Martinez Nene A, Srivatsan CD, Putnam contains defects in cancers Saccharomyces cerevisiae and rearrangements in suppresses genome that network A genetic 13 Apr Nature Communications 2016 SanLudwig Diego Diehn M, Alizadeh AA. Alizadeh M, Diehn HA, Wakelee JW, Jr, Neal BW Loo JB, Jr, GW Shrager Sledge RB, West JN, Carter L, C, Zhou Say SV, Bratman CL, F, Liu H, Stehr Scherer JJ, Chabon DM, Kurtz DM, AF, Klass Lovejoy AM, Newman DNA detection of circulating tumor suppression for improved Integrated digital error Nature Biotechnology 2016 May IL. Weissman Stem Cells Are Everywhere 2016 15 July Tumblehome Learning, Inc. Stanford Ludwig M. PJ, Gyrd-Hansen Damgaard RB, Komander D, Jost PR, Elliott M, Yabal K, D, Bagola Leske M, Zucca BK, Fiil M, Hrdinka immune signaling complexes to regulate innate linked ubiquitin at receptor CYLD limits Lys63- and Met1- 2016 29 March Reports Cell Sandberg R, Lanner F. Lanner R, Sandberg S, Linnarsson A, Reyes Plaza S4, Codeluppi SP3, Panula Q, Deng B, D, Reinius Edsgärd S, Petropoulos preimplantation embryos dynamics in human lineage and X chromosome reveals RNA-Seq Single-cell 2016 5 Cell May Stockholm Ludwig Weissman IL. Weissman JA, Norton GA, Poultsides BC, Visser TA, J,Longacre Sage PK, PJ, Mazur Schnorr JK, Nguyen RL, Yanovsky AJ, D, Zemek Sahoo AM, Newman N, Jahchan K, Weiskopf SB, VolkmerWillingham JP, BM, GW, George Krampitz tumors in pancreatic neuroendocrine cells and therapeutic targets Identification of tumorigenic 19 April 2016 USA Sciences of Academy Proceedings of the National Moustakas A. CH, Heldin M, Zerial M, Bickle AK, TC, Shiau D, Gahman Kardassis A, Morén A, Heldin M, Vanlandewijck C, Bellomo M, Stöter JM, Carthy myofibroblast differentiation receptor pathway controlling anuclear reveal plasticity Chemical regulators of epithelial 2016 19 July Reports Scientific Ludwig Uppsala

LUDWIG LINK | AUGUST 2016

LUDWIGCANCERRESEARCH.ORG